文献速递肝病

肝脏脂肪变性与主要不良心血管事件的关联独立于冠状动脉疾病

Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-21

基于PROMISE研究的嵌套队列纳入3756例接受冠状动脉CTA的有症状门诊患者,中位随访25个月。肝脏脂肪变性者主要不良心血管事件(MACE)发生率为4.4%,无脂肪变性者为2.6%(HR 1.69,95%CI 1.16-2.48,P=.006),校正心血管风险评分、显著狭窄及代谢综合征或肥胖后关联仍独立存在。

要点

  • 肝脏脂肪变性与MACE风险升高独立相关(校正HR 1.72,95%CI 1.16-2.54,P=.007)。
  • 该关联独立于基线冠状动脉斑块和狭窄的CTA评估结果。
  • 减少肝脏脂肪变性的策略可能降低MACE风险。

核心结论

  • 肝脏脂肪变性与MACE独立相关,不依赖于其他心血管危险因素或冠状动脉疾病范围。
  • 减少肝脏脂肪变性的策略可能降低MACE风险。

研究设计与样本

  • PROMISE研究的嵌套队列研究,纳入3756例受试者(平均年龄60.6岁,48.4%为男性),来自北美193个中心,2010年7月至2013年9月接受冠状动脉CTA。
  • 纳入对象为无冠状动脉疾病的有症状门诊患者,接受无创心血管分析。
  • 独立核心实验室阅片者使用非对比CT图像测量肝脏和脾脏衰减以判定脂肪变性,并评估冠状动脉CTA图像中的斑块和狭窄。
  • 收集心血管危险因素、代谢综合征和体重指数数据。
  • 主要终点为裁决的MACE复合终点(死亡、心肌梗死或不稳定型心绞痛),中位随访25个月。

主要发现

  • 959例受试者存在脂肪变性(占队列25.5%),其中42例发生MACE(4.4%)。
  • 2797例无脂肪变性受试者中73例发生MACE(2.6%)。
  • 脂肪变性 vs 无脂肪变性者MACE的HR为1.69(95%CI 1.16-2.48,P=.006)。
  • 校正动脉粥样硬化性心血管疾病风险评分、显著狭窄和代谢综合征后,校正HR为1.72(95%CI 1.16-2.54,P=.007)。
  • 校正肥胖后,校正HR为1.75(95%CI 1.19-2.59,P=.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatic steatosis has been associated with increased risk of major adverse cardiovascular events (MACE) but it is not clear whether steatosis is independently associated with risk of MACE. We investigated whether steatosis is associated with risk of MACE independently of the presence and extent of baseline coronary artery disease, assessed by comprehensive contrast-enhanced computed tomography angiography (CTA). METHODS: We conducted a nested cohort study of 3756 subjects (mean age, 60.6 years; 48.4% men) who underwent coronary CTA at 193 sites in North America, from July 2010 through September 2013, as part of the PROMISE study, which included noninvasive cardiovascular analyses of symptomatic outpatients without coronary artery disease. Independent core laboratory readers measured hepatic and splenic attenuation, using non-contrast computed tomography images to identify steatosis, and evaluated coronary plaques and stenosis in coronary CTA images. We collected data on participants' cardiovascular risk factors, presence of metabolic syndrome, and body mass index. The primary endpoint was an adjudicated composite of MACE (death, myocardial infarction, or unstable angina) during a median follow-up time of 25 months. RESULTS: Among the 959 subjects who had steatosis (25.5% of the cohort), 42 had MACE (4.4%), whereas among the 2797 subjects without steatosis, 73 had MACE (2.6%) (hazard ratio [HR] for MACE in subjects with steatosis, 1.69; 95% CI, 1.16-2.48; P = .006 for MACE in subjects with vs without steatosis). This association remained after adjustment for atherosclerotic cardiovascular disease risk scores, significant stenosis, and metabolic syndrome (adjusted HR, 1.72; 95% CI, 1.16-2.54; P = .007) or obesity (adjusted HR, 1.75; 95% CI, 1.19-2.59; P = .005). Steatosis remained independently associated with MACE after adjustment for all CTA measures of plaques and stenosis. CONCLUSIONS: Hepatic steatosis is associated with MACE independently of other cardiovascular risk factors or extent of coronary artery disease. Strategies to reduce steatosis might reduce risk of MACE. ClinicalTrials.gov no: NCT01174550.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Meyersohn NM, Mayrhofer T, Corey KE, et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32707340. doi:10.1016/j.cgh.2020.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。